Search research articles
Contact Us
Filters
Showing results (121-130 of 138) with videos related to
Page
of 14
Sort By:
Lung Cancer (Amsterdam, Netherlands)
|
September 20, 2024
Patient-reported outcomes in CodeBreaK 200: Sotorasib versus docetaxel for previously treated advanced NSCLC with KRAS G12C mutation
David M Waterhouse, Sacha Rothschild, Christophe Dooms, et al.
European Journal of Cancer (Oxford, England : 1990)
|
July 19, 2024
Sotorasib (960 mg or 240 mg) once daily in patients with previously treated KRAS G12C-mutated advanced NSCLC
Maximilian J Hochmair, Karim Vermaelen, Giannis Mountzios, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 25, 2023
Long-Term Outcomes and Molecular Correlates of Sotorasib Efficacy in Patients With Pretreated <i>KRAS</i> G12C-Mutated Non-Small-Cell Lung Cancer: 2-Year Analysis of CodeBreaK 100
Grace K Dy, Ramaswamy Govindan, Vamsidhar Velcheti, et al.
Future Oncology (London, England)
|
November 27, 2023
Long-term benefit of sotorasib in patients with KRAS G12C-mutated non-small-cell lung cancer: plain language summary
Grace K Dy, Ramaswamy Govindan, Vamsidhar Velcheti, et al.
Cell Research
|
January 21, 2021
Discriminating mild from critical COVID-19 by innate and adaptive immune single-cell profiling of bronchoalveolar lavages
Els Wauters, Pierre Van Mol, Abhishek Dinkarnath Garg, et al.
Clinical Chemistry
|
June 30, 2022
Pan-Cancer Detection and Typing by Mining Patterns in Large Genome-Wide Cell-Free DNA Sequencing Datasets
Huiwen Che, Tatjana Jatsenko, Liesbeth Lenaerts, et al.
European Journal of Cardio-Thoracic Surgery : Official Journal of the European Association for Cardio-Thoracic Surgery
|
October 14, 2017
Multicentric evaluation of the impact of central tumour location when comparing rates of N1 upstaging in patients undergoing video-assisted and open surgery for clinical Stage I non-small-cell lung cancer†
Herbert Decaluwé, René Horsleben Petersen, Alex Brunelli, et al.
BMC Cancer
|
June 17, 2020
Stereotactic ablative body radiotherapy (SABR) combined with immunotherapy (L19-IL2) versus standard of care in stage IV NSCLC patients, ImmunoSABR: a multicentre, randomised controlled open-label phase II trial
Relinde I Y Lieverse, Evert J Van Limbergen, Cary J G Oberije, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 22, 2023
Initial Evidence for the Efficacy of Naporafenib in Combination With Trametinib in <i>NRAS</i>-Mutant Melanoma: Results From the Expansion Arm of a Phase Ib, Open-Label Study
Filippo de Braud, Christophe Dooms, Rebecca S Heist, et al.
Clinical Lung Cancer
|
January 16, 2026
Patient-Relevant Outcomes From the Phase III MARIPOSA-2 Trial: Amivantamab-Chemotherapy Versus Chemotherapy in EGFR-Mutant Advanced Non-Small-Cell Lung Cancer Following Disease Progression on Osimertinib
Pascale Tomasini, Oscar Juan-Vidal, Raffaele Califano, et al.
Page
of 14
Search research articles
Search
Showing results (121-130 of 138) with videos related to
Sort By:
Page
of 14
Lung Cancer (Amsterdam, Netherlands)
|
September 20, 2024
Patient-reported outcomes in CodeBreaK 200: Sotorasib versus docetaxel for previously treated advanced NSCLC with KRAS G12C mutation
David M Waterhouse, Sacha Rothschild, Christophe Dooms, et al.
European Journal of Cancer (Oxford, England : 1990)
|
July 19, 2024
Sotorasib (960 mg or 240 mg) once daily in patients with previously treated KRAS G12C-mutated advanced NSCLC
Maximilian J Hochmair, Karim Vermaelen, Giannis Mountzios, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 25, 2023
Long-Term Outcomes and Molecular Correlates of Sotorasib Efficacy in Patients With Pretreated <i>KRAS</i> G12C-Mutated Non-Small-Cell Lung Cancer: 2-Year Analysis of CodeBreaK 100
Grace K Dy, Ramaswamy Govindan, Vamsidhar Velcheti, et al.
Future Oncology (London, England)
|
November 27, 2023
Long-term benefit of sotorasib in patients with KRAS G12C-mutated non-small-cell lung cancer: plain language summary
Grace K Dy, Ramaswamy Govindan, Vamsidhar Velcheti, et al.
Cell Research
|
January 21, 2021
Discriminating mild from critical COVID-19 by innate and adaptive immune single-cell profiling of bronchoalveolar lavages
Els Wauters, Pierre Van Mol, Abhishek Dinkarnath Garg, et al.
Clinical Chemistry
|
June 30, 2022
Pan-Cancer Detection and Typing by Mining Patterns in Large Genome-Wide Cell-Free DNA Sequencing Datasets
Huiwen Che, Tatjana Jatsenko, Liesbeth Lenaerts, et al.
European Journal of Cardio-Thoracic Surgery : Official Journal of the European Association for Cardio-Thoracic Surgery
|
October 14, 2017
Multicentric evaluation of the impact of central tumour location when comparing rates of N1 upstaging in patients undergoing video-assisted and open surgery for clinical Stage I non-small-cell lung cancer†
Herbert Decaluwé, René Horsleben Petersen, Alex Brunelli, et al.
BMC Cancer
|
June 17, 2020
Stereotactic ablative body radiotherapy (SABR) combined with immunotherapy (L19-IL2) versus standard of care in stage IV NSCLC patients, ImmunoSABR: a multicentre, randomised controlled open-label phase II trial
Relinde I Y Lieverse, Evert J Van Limbergen, Cary J G Oberije, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 22, 2023
Initial Evidence for the Efficacy of Naporafenib in Combination With Trametinib in <i>NRAS</i>-Mutant Melanoma: Results From the Expansion Arm of a Phase Ib, Open-Label Study
Filippo de Braud, Christophe Dooms, Rebecca S Heist, et al.
Clinical Lung Cancer
|
January 16, 2026
Patient-Relevant Outcomes From the Phase III MARIPOSA-2 Trial: Amivantamab-Chemotherapy Versus Chemotherapy in EGFR-Mutant Advanced Non-Small-Cell Lung Cancer Following Disease Progression on Osimertinib
Pascale Tomasini, Oscar Juan-Vidal, Raffaele Califano, et al.
Page
of 14